Get all your news in one place.
100's of premium titles.
One app.
Start reading
The Independent UK
The Independent UK
Health
Julia Musto

Weight-loss meds go head-to-head in new study. One was significantly more effective, drugmaker says

In a new head-to-head trial, drugmaker Eli Lilly said Wednesday that patients using its obesity medication Zepbound lost significantly more weight than those who were given competitor Novo Nordisk’s Wegovy.

Eli Lilly said that users of Zepbound, which contains the antidiabetic medication tirzepatide, shed 47 percent more pounds compared to those who were given the other semaglutide drug.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.